Trial reportAlcoholism, clinical and experimental research2015
A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder.
Trial report in Alcoholism, clinical and experimental research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03894345 (Open Label 8-Week Study of Prazosin Use in Adults With Anxiety Disorders), which is not on this map. Cited by 50 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Open Label 8-Week Study of Prazosin Use in Adults With Anxiety Disorders
Who cites it
50 citing papers in PubMed, 7 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Treatment for co-occurring posttraumatic stress disorder and substance use disorders among veterans and civilians: A test of causally moderated comparative effectiveness.Psychological trauma : theory, research, practice and policy · 2026Pooled it
- Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients - a systematic review and meta-regression analysis.Progress in neuro-psychopharmacology & biological psychiatry · 2025Pooled it
- Project harmony: A systematic review and network meta-analysis of psychotherapy and pharmacologic trials for comorbid posttraumatic stress, alcohol, and other drug use disorders.Psychological bulletin · 2024Pooled it
- Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders.The American journal of psychiatry · 2023Pooled it
- The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials.International journal of environmental research and public health · 2022Pooled it
- Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches.European journal of psychotraumatology · 2021Pooled it
- The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis.Sleep medicine · 2020Pooled it
- Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder.Alcoholism, clinical and experimental research · 2020Trial
- Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder.NeuroImage. Clinical · 2020Trial
- Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder.Alcoholism, clinical and experimental research · 2019Trial
- Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.The American journal of psychiatry · 2018Trial
- Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin.Drug and alcohol dependence · 2017Trial
- A Randomized, Placebo-controlled, Clinical Trial of Prazosin for the Treatment of Alcohol Use Disorder.Journal of addiction medicineTrial
- Prazosin in the Pharmacologic Management of Alcohol Use Disorder.Biological psychiatry global open science · 2026Article
- Prazosin-Related Reductions in Daily Craving Mediate Treatment-Related Daily Alcohol Use Outcomes in Alcohol Use Disorder.Biological psychiatry global open science · 2026Article
- Spironolactone and clinical outcomes in patients with alcohol use disorder and comorbid hypertension: a target trial emulation study.Psychopharmacology · 2026Article
- Noradrenaline Modulates Central Amygdala GABA Transmission and Alcohol Drinking in Female Rats.Biological psychiatry · 2026Article
- Noradrenergic Mechanisms and Circuitry of Hyperkatifeia in Alcohol Use Disorder.Biological psychiatry · 2025Review
- Doxazosin for the treatment of mental health disorders: A scoping review.PLOS mental health · 2025Article
- Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders.Journal of medicinal chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundPosttraumatic stress disorder (PTSD) and alcohol dependence (AD) commonly co-occur and are associated with greater symptom severity and costs than either disorder alone. No pharmacologic interventions have been found to decrease both alcohol use and PTSD symptom severity relative to matched placebo. Prazosin, an alpha-1 adrenoreceptor antagonist, has demonstrated the efficacy of reducing PTSD and AD symptoms among individuals with one or the other disorder and may be useful in addressing comorbid PTSD/AD.
methodsPrazosin and matched placebo were compared in the context of an outpatient 6-week double-blind randomized controlled pilot trial involving 30 individuals with comorbid PTSD/AD. Medication was titrated to 4 mg q am, 4 mg q pm and 8 mg qhs by the end of week 2. Participants in both conditions received 5 medical management sessions. Information regarding alcohol use, craving, and PTSD was gathered daily using a telephone interactive voice response system.
resultsParticipants randomized to prazosin had a greater reduction in percent days drinking per week and percent days heavy drinking per week between baseline and week 6 than did placebo participants. No significant differences were detected within or between groups in change from weeks 1 to 6 in total PTSD symptoms. Participants in the prazosin condition reported drowsiness on significantly more days than those in the placebo condition.
conclusionsConsistent with the extant research evaluating medications for comorbid PTSD/AD, the current evaluation of prazosin also found decreased alcohol consumption but no medication effect on PTSD symptomatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.